Overview


According to FutureWise analysis the market for anthrax treatment in 2023 is US$ 0.6 billion, and is expected to reach US$ 1.08 billion by 2031 at a CAGR of 7.60%.

It mainly affects farm animals but can infect humans through contact with contaminated animals or their products and even through heroin injection. Laboratory workers and those potentially exposed to bioterrorism are also at risk. Notably, anthrax is not contagious, requiring swift medical attention upon exposure. The infection is caused by Bacillus anthracis bacteria, which form spores in soil, remaining viable for years. Upon entry into the body, spores release bacteria that produce toxins causing illness.

Transmission can occur through inhalation, ingestion, or skin cuts, leading to distinct symptoms. Skin exposure leads to itchy blisters or painless sores with swelling. Ingesting contaminated items may result in fever, swollen neck or glands, nausea, vomiting (possibly bloody), diarrhoea, headache, and red eyes and face. Inhalation poses the highest risk, causing flu-like symptoms, breathlessness, coughing blood, and severe outcomes like meningitis. Injection anthrax from heroin use triggers itchy blisters, fever, ulcers, pus pockets, and potential organ failure. Diagnosis involves blood tests for antibodies or toxins. Samples from skin, spinal fluid, stool, and mucus are examined. Imaging and chest X-rays assist in inhalation cases. Treatment hinges on exposure type and includes antibiotics and antitoxins like obiltoxaximab or raxibacumab, particularly for inhalation of anthrax. Severe cases necessitate hospitalization. The anthrax vaccine is advised for at-risk groups such as lab and military personnel and those working with animals. Although not standard after exposure, emergencies may call for vaccination and antibiotics in potential terrorism scenarios.

FutureWise Market Research has published a report that provides an insightful analysis of Anthrax Treatment Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that Anthrax Treatment Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Glaxo SmithKline Pharmaceuticals Ltd.
  • Elusys Therapeutics, Inc.
  • Emergent BioSolutions, Inc.
  • PharmAthene, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Bayer AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Development in Anthrax Treatment Market

  • In April 2022, NightHawk Biosciences successfully concluded the acquisition of Elusys Therapeutics, Inc., a biodefense company operating at the commercial stage and known for its development of ANTHIM (obiltoxaximab), an inhalation anthrax treatment.

  • Furthermore, in January 2022, Elusys Therapeutics formalized an agreement with the office of the assistant secretary for preparedness and response (ASPR) within the United States Department of Health and Human Services (HHS). This agreement centered on ensuring the ongoing supply of ANTHIM (obiltoxaximab), an anthrax antitoxin, for potential employment in countering an anthrax attack.

On the driver's side, the increasing global awareness regarding bioterrorism threats and the potential use of anthrax as a biological weapon have driven governments and healthcare organizations to invest in anthrax treatment solutions. The need for preparedness in the face of bioterrorism incidents has prompted research and development in anthrax treatment, resulting in advanced therapies and vaccines. Moreover, the expanding base of laboratory workers, military personnel, and individuals working with animals at higher risk of anthrax exposure has necessitated the development and availability of effective treatment options, including vaccines and antitoxins. Furthermore, technological advancements in medical research and a growing understanding of anthrax biology have contributed to developing targeted therapies to mitigate the severity of anthrax infections and improve patient outcomes.

However, the market also encounters significant restraints. The rare anthrax cases, particularly in regions with advanced healthcare systems, can limit the commercial viability of investing in research and development of anthrax treatments. The complexities of manufacturing and distributing anthrax-specific treatment solutions, such as vaccines and antitoxins, pose challenges, as these products may have limited market demand outside emergencies. Regulatory hurdles associated with the approval process for anthrax treatment solutions, given the specialized nature of the condition, can also hinder the introduction of new products to the market. Moreover, concerns about the cost-effectiveness of investing in anthrax treatments, especially compared to other healthcare priorities, may impact investment decisions and market growth.

By Anthrax Type

  • Cutaneous Anthrax
  • Inhalation Anthrax
  • Gastrointestinal Anthrax
  • Injection Anthrax

By Drug Class

  • Fluoroquinolone
  • Tetracycline
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • e-commerce
  • Drug Stores
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. In the Anthrax Treatment Market. North America is positioned as a dominant force in the global anthrax treatment market due to robust government funding, strategic support, and the significant presence of key industry players. While anthrax remains infrequent in the United States, sporadic outbreaks affecting wild and domestic grazing animals have spurred annual livestock vaccinations in areas with prior anthrax incidents. Different forms of anthrax infections can be effectively treated using antibiotics, including intravenous options and tailored medications. Anthrax Vaccine Adsorbed (AVA), or BioThrax, holds licensure as an anthrax vaccine designed for active immunization against Bacillus anthracis infection in individuals aged 18–65, particularly those at heightened risk. These factors underpin the projected growth of the anthrax treatment market in North America.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Anthrax Treatment Market By Anthrax Type, By Drug Class, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Anthrax Treatment Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Anthrax Treatment Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Anthrax Treatment Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Anthrax Treatment Market, By Anthrax Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cutaneous Anthrax
        2. Inhalation Anthrax
        3. Gastrointestinal Anthrax
        4. Injection Anthrax

  • 8.   Anthrax Treatment Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Fluoroquinolone
        2. Tetracycline
        3. Others

  • 9.   Anthrax Treatment Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. e-commerce
        4. Drug Stores
        5. Others

  • 10.   North America Anthrax Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Anthrax Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Anthrax Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Anthrax Treatment Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Glaxo SmithKline Pharmaceuticals Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Elusys Therapeutics, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Emergent BioSolutions, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. PharmAthene, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Teva Pharmaceutical Industries Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Novartis AG
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bayer AG
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Anthrax Vaccines Market

Read More
Partner

Our Clients